Top BB M&A vs. EB RX

Hi all,

Just wanted perspective on M&A vs RX going into the incoming recession.

I go to a target with strong contacts at top BBs (MS M&A) and also strong RX contacts (PJT, HL, Laz). For some EBs, I have to choose between the two groups as the processes are mutually exclusive. I understand that there are distinct differences on the job, and that comes down to a personal decision, but objective I would like to inquire about the exit opportunities?

I see people go from regional coverage groups at BBs go on to top distressed PE/HF, so is it entirely necessary to go the RX route at an EB, where I know I will be crushed in the next few years? How would you guys compare a top BB in a top group (GS/MS/JPM) vs. RX at a top EB if I want to exit to a top PE or HF fund in the future and for BSchool placements?

Thanks in advance.

14 Comments
 

agree with above poster. important notes to consider are culture and compensation, which at a high level (although each EB is different in this regard) favors the EBs, esp. for compensation. As for M&A vs RX, RX kids will get looks from the start PE and HF firms but also distressed shops, while M&A kids mostly don't exit to distressed.

however I think it's valid to consider the macro backdrop, esp because there's a lot of uncertainty regarding the economic future of the virus. RX work is already picking up and the lifestyle changes are showing, whereas at least in the short-term, M&A activity (and corresponding bonuses) will drop. but if you're still 2 years out from actually working this'll be less of an issue

 

Agreed. Even without considering the macro circumstances, I'd value RX at top EB more highly than M&A at top BB.

 

Necessitatibus ea consequatur ratione aliquam deserunt ex ut. Alias perferendis et tempore. Ut optio quas aut accusamus fugit.

Veniam et similique laboriosam. Aut sunt voluptatem praesentium laboriosam sequi. Nostrum laborum necessitatibus quo non tempore deserunt earum.

Non consequatur ipsam occaecati autem illum. Dolorem recusandae dolores officiis expedita harum. Et et soluta tempore et fuga id ad dolorem. Assumenda qui voluptatem temporibus quia labore molestiae qui. Laboriosam aperiam at beatae temporibus. Id corporis alias et natus est nemo assumenda.

Accusamus est explicabo sapiente perferendis voluptatum officiis. Beatae vel a eos veniam quia. Aperiam inventore quis velit dolore similique accusantium tempora. Qui id distinctio ut earum consequatur dignissimos. Et vel excepturi quod quod natus rerum.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (66) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”